Although there is growing epidemiological, preclinical and clinical evidence suggesting that low vitamin D intake, exposure and/or status is associated with an increased risk of various types of cancer, the optimum amount needed remains controversial. Furthermore, there is evidence that a U- or J-shaped response curve exist between 25(OH)D and certain cancers. Increasing information about the impact of genetic variation, especially polymorphisms that influence absorption, transport, metabolism and associated molecular targets, should help clarify inconsistencies in the data regarding vitamin D’s effect on cancer risk. Rather than focusing on the main effects of a few variants of these genes alone, future studies need to consider gene-nutrient or environmental interactions. Nutrigenomics should clarify who might benefit and be placed at risk because of vitamin D exposure.

Keywords:
Vitamin D, Cancer prevention, Vitamin D receptor, Nutrigenomics, Biomarkers, Polymorphisms
1.
Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, Moshfegh AJ, Sempos CT, Picciano MF: Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010;140:817–822.
2.
Armas LA, Dowell S, Akhter M, Duthuluru S, Huerter C, Hollis BW, Lund R, Heaney RP: Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J Am Acad Dermatol 2007;57:588–593.
3.
Daiger SP, Schanfield MS, Cavalli-Sforza LL: Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci USA 1975;72:2076–2080.
4.
Jones G: Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S–586S.
5.
Talwar SA, Aloia JF, Pollack S, Yeh JK: Dose response to vitamin D supplementation among postmenopausal African-American women. Am J Clin Nutr 2007;86:1657–1662.
6.
Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ: Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204–210.
7.
Aloia JF, Patel M, Dimaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK: Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 2008;87:1952–1958.
8.
Cashman KD, Hill TR, Lucey AJ, Taylor N, Seamans KM, Muldowney S, Fitzgerald AP, Flynn A, Barnes MS, Horigan G, Bonham MP, Duffy EM, Strain JJ, Wallace JM, Kiely M: Estimation of the dietary requirement for vitamin D in healthy adults. Am J Clin Nutr 2008;88:1535–1542.
9.
Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C: Pancreatic cancer cells express 25-hydroxyvitamin D-1-(-hydroxylase and their proliferation is inhibited by the prohormone, 25-hydroxyvitamin D3. Carcinogenesis 2004;25:1015–20.
10.
Garland CF, Garland FC: Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227–231.
11.
Hanchette CL, Schwartz GG: Geographinc patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861–2869.
12.
Murillo G, Matusiak D, Benya RV, Mehta RG: Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem and Molec Biol 2007;103:763–767.
13.
Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, Munoz A: Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 2006;26:2669–2881.
14.
Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, Holick MF: Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/C mice. J Nutr 2005;135:2350–2354.
15.
Cross HS, Bises G, Lechner D, Manhardt T, Kallay E: The vitamin D endocrine system of the gut: its possible role in colorectal cancer prevention. J Steroid Biochem Molec Biol 2005;97:121–128.
16.
Garland CF, Grant WB, Mohr SB, Gorham ED, Garland FC: What is the dose-response relationship between vitamin D and cancer risk? Nutr Rev 2007;65:S91–S95.
17.
Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF: Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Preventive Med 2007;32:210–216.
18.
Rohan T: Epidemiological studies of vitamin D and breast cancer. Nutr Rev 2007;65:S80–S83.
19.
Giovannucci E: Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate cancer risk. Nutr Rev 2007;65:S77–S79.
20.
Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P: Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2010, Epub ahead of print.
21.
IARC: Vitamin D and Cancer. IARC Working Group Reports, vol 5. Lyon, International Agency for Research on Cancer, 2008.
22.
Tuohimaa P, Tenkanen L, Ahonen M, Summe S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M: Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104–108.
23.
Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang W, Shikany JM, Hayes RB: Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008;100:796–804.
24.
Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer.J Clin Oncol 2009;27:3757–3763.
25.
Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, Albanes D: A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006;66:10213–10219.
26.
Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT: Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009;69:1439–1447.
27.
Chen W, Dawsey SM, Qiao Y-L, Mark SD, Dong Z-W, Taylor PR, Zhao P, Abnet CC: Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer 2007;97:123–128.
28.
Abnet CC, Chen W, Dawsey SM, Wei W, Roth MJ, Liu B, Lu N, Taylor PR, Qiao Y: Serum 25(OH)-vitamin D concentration and risk of esophageal squamous dysplasia. Cancer Epidemiol Biomarkers Prev 2007;16:1889–1893.
29.
Toner CD, Davis CD, Milner JA: The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc 2010;110:1492–1500.
30.
Raimondi S, Johansson H, Maisonneuve P, Gandini S: Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009;30:1170–1180.
31.
Rukin NJ, Strange RC: What are the frequency, distribution and functional effects of vitamin D receptor polymorphisms as related to cancer risk? Nutr Rev 2007;65:S96–S101.
32.
Uitterlinden SG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP: Genetics and biology of vitamin D receptor polymorphism. Gene 2004;338:143–156.
33.
Zmuda JM, Cauley JA, Ferell RE: Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 2000;22:203–217.
34.
Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Haussler CA, Galligan MA, Thatcher ML, Encinas Doninguez C, Haussler MR: Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001;177:145–159.
35.
Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P, Galligan MA, Dang HT, Haussler CA, Haussler MR: The polymorphic N-terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interactions with transcription factor IIB. Mol Endocrinol 2000;14:401–420.
36.
Orton SM, Morris AP, Herrera BM, Ramagopalan SV, Lincoln MR, Chao MJ, Vieth R, Sadovnick AD, Ebers GC: Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008;88:441–447.
37.
Slattery ML, Murtaugh M, Caan B, Ma KN, Wolff R, Samowitz W: Associations between BMI, energy intake, energy expenditures, VDR genotype and colon and rectal cancers (United States). Cancer Causes Control 2004;9:863–872.
38.
Wong HL, Seow A, Arakawa K, Lee HP, Yu MC, Ingles SA: Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 2003;24:1091–1095.
39.
McCullough ML, Bostick RM, Mayo TL: Vitamin D gene pathway polymorphism and risk of colorectal, breast, and prostate cancer. Ann Rev Nutr 2009;29:111–132.
40.
Ebert R, Schutze N, Adamski J, Jakob F: Vitamin D signaling is modulated on multiple levels in health and disease. Mol Cell Endocrinol 2006;248:149–159.
41.
Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, White E, Slattery ML, Farin FM, Makar KW, Carlson CS, Caan BJ, Potter JD, Peters U: Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:2540–2548.
42.
Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, Bowden DW, Norris JM: Genetic and environmental determines of 25-hydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 2008;93:3381–3388.
43.
Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L: Plasma concentrations of 25-hydroxyvitamin D and 1,25-dihydoxy-vitamin D are related to the phenotype of Gc(vitamin D-binding protein): a cross sectional study on 595 postmenopausal women. Calcif Tissue Int 2005;77:15–22.
44.
Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D: Genome-wide association study of circulating vitamin D levels. Human Molecular Genet 1010;19:2739–2745.
45.
Fleet J: What have genomic and proteomic approaches told us about vitamin D and cancer? Nutr Rev 2007;65:S127–S130.
46.
Kriebitzsch C, Verlinden L, Eelen G, Tan BK, Camp MV, Bouillon R, Verstuyf A: The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells-a microarray approach. Anticancer Res 2009;29:3471–3484.
47.
Wang QM, Jones JB, Studzinski GP: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL-60 cells. Cancer Res 1996;56:264–267.
48.
Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, Bai W: Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J Boil Chem 2005;280:35458–35468.
49.
Townsend K, Trevino V, Falciani F, Stewart PM, Hewison M, Campbell MJ: Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 2006;71:111–123.
50.
Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP: Transcription of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142–153.
51.
Moffatt KA, Johannes WU, Hedlund TE, Miller GJ: Growth inhibitory effects of 1 alpha, 25-dihydroxyviatim D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 2004;64:2143–2147.
52.
Zhuang SH, Burnstein KL: Antiproliferative effect of 1 alpha,25-dihydroxyviatmin D3 in human prostate cancer cell line LNCaP involved reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197–1207.
53.
Boyle BJ, Zhao XY, Cohen P, Feldman D: Insulin-like growth factor binding protein-3 mediates 1,25-dihydroxyviatimin D growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319–1324.
54.
Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S: Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev 2007;65:S113–S115.
55.
Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C: Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1(,25-dihydroxyvitamin D3. J Mol Biol 2005;350:65–77.
56.
Turunen MM, Dunlop TW, Carlberg C, Vaisanen S: Selective use of multiple vitamin D response elements underlies the 1(,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acid Res 2007;35:2734–2747.
57.
Sinkkonen L, Malinen M, Saavalainen K, Vaisanen S, Carlberg C: Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter. Nucleic Acids Res 2005;33:2440–2451.
58.
Saramaki A, Banwell CM, Campbell MJ, Carlberg C: Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acid Res 2006;34:543–554.
59.
Carlberg C, Seuter S: A genomic perspective on vitamin D signaling. Anticancer Res 2009;29:3485–3494.
60.
Zella LA, Kim S, Shevde NK, Pike JW: Enhances located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol Endocrinol 2006;20:1231–1247.
61.
Meyer MB, Watanuki M, Kim S, Shevde NK, Pike JW: the human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol 2006;20:1447–1461.
62.
Fretz JA, Zella LA, Kim S, Shevde NK, Pike JW: 1,25-Dihydroxyvitamin D3 induces expression of the Wnt signaling co-regulator LRP5 via regulatory elements located significantly downstream of the gene’s transcriptional start site. J Ster Biochem Molec Biol 2007;103:440–445.
63.
Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW: Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long range enhancers. Mol Cell Boil 2006;26:6469–6486.
64.
Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni r, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V: Modulation of the vitamin D3 response by cancer associated mutant p53. Cancer Cell 2010;17:273–285.
65.
Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T: MicroRNA regulates human vitamin D receptor. Int J Cancer 2009;125:1328–1333.
66.
Komagata S, Nakajima M, Takagi S, Mohri T, Tanija T, Yokoi T: Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptional regulation by miR-125b. Mol Pharmacol 2009;76:702–709.
67.
Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF: Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003;88:315–322.
68.
Hsu JY, Feldman D, McNeal JE, Peehl DM: Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001;61:2852–2856.
69.
Weigel NL: Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev 2007;65:S116–S117.
70.
Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF: Prostatic 25-hydroxyviatim D-1-(-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003;88:315–322.
71.
Friedrich M, Diesing D, Cordes T, Fischer D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick MF, Reichrath J: Analysis of the 25-hydroxyvitamin D3-1-alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res 2006;26:2615–2620.
72.
Matusiak D, Murillo G, Carroll RE, Mehta RG, Benya RV: Expression of vitamin D receptor and 25-hydroxyvitamin D3–1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 2005;14:2370–2376.
73.
Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144–146.
74.
Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR: Expression of VDE and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234–240.
75.
Matusiak D, Benya RV: CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J Histochem Cytochem 2007;55:1257–1264.
76.
Bikle DD, Rasmussen H: The ionic control of 1,25-dihydroxyvitamin D3 production in isolated chick renal tubules. J Clin Invest 1975;55:292–298.
77.
Cross HS, Lipkin M, Kállay E: Nutrients regulate the colonic vitamin D system in mice: relevance for human colon malignancy. J Nutr 2006;136:561–564.
78.
Cross HS, Kallay E: Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol 2009;5:493–507.
79.
Cross H: Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells. Nutr Rev 2007;65:S108–S112.
80.
Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD: Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 2002;132:3191–3194.
81.
Rao A, Coan A, Welsh J, Barclay WW, Koumenis C, Cramer SD: Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004;64:2143–2147.
82.
Mawer EB, Backhouse J, Holman CA, Lumb GA, Standbury SW: The distribution and storage of vitamin D and its metabolites in human tissues. Clin Sci 1972;43:413–431.
83.
Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH: Low circulating vitamin D in obesity. Calcific Tissue Int 1988;43:199–201.
84.
Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S: Evidence of alteration in the vitamin D-endocrine system in obese subjects. J Clin Invest 1985;76:370–373.
85.
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690–693.
86.
Rosensterich SJ, Rich C, Volwiler W: Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat. J Clin Invest 1971;50:679–687.
87.
Brouwer DA, van Beek J, Ferwerda H, Brugman AM, van der Klis FR, van der Heiden HJ, Muskiet FA: Rat adipose tissue rapidly accumulates and slowly releases an orally-administered high vitamin D dose. Br J Nutr 1998;79:527–532.
88.
Lagunova Z, Porojinicu AC, Grant WB, Bruland O, Moan JE: Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res 2010;54:1–7.
89.
Teegarden D, White KM, Lyle RM, Zemel MB, Van Loan MD, Matkovic V, Craig BA, Schoeller DA: Calcium and dairy product modulation of lipid utilization and energy expenditure. Obesity 2008;16:1566–1572.
90.
Ortega RM, Aparicio A, Rodriguez-Rodriguez E, Bermejo LM, Perea JM, López-Sobaler AM, Ruiz-Roso B, Andrés P: Preliminary data about the influence of vitamin D status on the loss of body fat in young overweight/obese women following two types of hypocaloric diet. Br J Nutr 2008;100:269–272.
91.
Looker AC: Do body fat and exercise modulate vitamin D status? Nutr Rev 2007;65:S124–S126.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.